Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 314 articles:
HTML format



Single Articles


    January 2022
  1. WANG M, Semerjian A, Lane BR, George AK, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
    J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
    PubMed    


  2. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
    J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
    PubMed     Abstract available


  3. PAN A, Reingold RE, Zhao JL, Moy A, et al
    Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
    J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
    PubMed     Abstract available


  4. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
    PubMed    


  5. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
    Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
    J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
    PubMed     Abstract available


  6. NAYAK JG
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
    J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
    PubMed    


  7. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
    J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
    PubMed    


  8. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
    The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
    PubMed     Abstract available


  9. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
    Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
    J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
    PubMed     Abstract available


  10. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
    Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
    J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
    PubMed     Abstract available


  11. LEE A, Chen K, Tay KJ
    Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
    J Urol. 2022;207:240-241.
    PubMed    


  12. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
    J Urol. 2022;207:241-242.
    PubMed    


  13. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
    Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
    J Urol. 2022;207:118-126.
    PubMed     Abstract available


  14. CHANG P, Wagner AA, Regan MM, Smith JA, et al
    Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
    J Urol. 2022;207:127-136.
    PubMed     Abstract available


  15. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
    Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    J Urol. 2022;207:95-107.
    PubMed     Abstract available


  16. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    J Urol. 2022;207:108-117.
    PubMed     Abstract available


    December 2021
  17. WASHINGTON SL 3RD, Gore JL, Nyame YA
    Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
    J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
    PubMed    


  18. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
    Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
    PubMed     Abstract available


  19. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
    PubMed    


  20. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
    Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
    PubMed     Abstract available


  21. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
    PubMed     Abstract available


  22. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
    MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
    PubMed     Abstract available


  23. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
    J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
    PubMed     Abstract available


  24. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
    Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
    J Urol. 2021;206:1403-1410.
    PubMed     Abstract available


    November 2021
  25. CHEN K, Murphy D, Lawrentschuk N
    Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
    J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
    PubMed    


  26. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
    PubMed    


  27. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
    Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
    J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
    PubMed    


  28. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
    J Urol. 2021;206:1192-1203.
    PubMed     Abstract available


  29. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
    Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
    J Urol. 2021;206:1184-1191.
    PubMed     Abstract available


    October 2021
  30. LEE MC, Erickson TR, Stock S, Howard LE, et al
    Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
    PubMed     Abstract available


  31. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
    Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
    J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
    PubMed     Abstract available


  32. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
    Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
    PubMed     Abstract available


  33. YU W, Guo J
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
    PubMed    


  34. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
    Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
    PubMed     Abstract available



  35. Urological Oncology: Prostate Cancer.
    J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
    PubMed    


  36. KAPLAN-MARANS E
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
    J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
    PubMed    


  37. ZHANG KW, Guha A
    Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
    J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
    PubMed    


  38. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
    Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
    J Urol. 2021;206:894-902.
    PubMed     Abstract available


  39. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
    A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
    J Urol. 2021;206:942-951.
    PubMed     Abstract available


    September 2021
  40. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
    PubMed     Abstract available


  41. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
    Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
    J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
    PubMed     Abstract available


  42. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
    An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
    J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
    PubMed     Abstract available


  43. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
    (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
    J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
    PubMed     Abstract available


  44. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
    Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
    PubMed     Abstract available


  45. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
    J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
    PubMed    


  46. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
    PubMed    


  47. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
    Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    J Urol. 2021;206:706-714.
    PubMed     Abstract available


  48. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
    The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
    J Urol. 2021;206:662-668.
    PubMed     Abstract available


  49. HINES L, Zhu D, DeMasi M, Babar M, et al
    A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
    J Urol. 2021;206:586-594.
    PubMed     Abstract available


  50. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
    Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
    J Urol. 2021;206:604-612.
    PubMed     Abstract available


    August 2021
  51. KIM M, Wu S, Lin SX, Crotty RK, et al
    Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
    J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
    PubMed     Abstract available


  52. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
    Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
    J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
    PubMed     Abstract available


  53. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
    PubMed    


  54. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
    Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
    J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
    PubMed     Abstract available


  55. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
    Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
    J Urol. 2021;206:325-337.
    PubMed     Abstract available


  56. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
    J Urol. 2021;206:289-297.
    PubMed     Abstract available


  57. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
    Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
    J Urol. 2021;206:346-353.
    PubMed     Abstract available


    July 2021
  58. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
    Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
    J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
    PubMed     Abstract available


  59. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
    PubMed    


  60. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
    Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
    PubMed     Abstract available


  61. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
    Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
    PubMed     Abstract available


  62. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
    Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
    J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
    PubMed     Abstract available


    June 2021
  63. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
    Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
    PubMed     Abstract available


  64. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
    J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
    PubMed     Abstract available


  65. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
    The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
    J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
    PubMed     Abstract available


  66. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
    PubMed    


  67. INABA H, Kimura T, Onuma H, Kido M, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
    J Urol. 2021;205:1841-1842.
    PubMed    


  68. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
    Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
    J Urol. 2021;205:1839-1840.
    PubMed    


  69. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
    Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
    J Urol. 2021;205:1663-1670.
    PubMed     Abstract available


  70. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
    National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
    J Urol. 2021;205:1641-1647.
    PubMed     Abstract available


  71. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
    Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
    J Urol. 2021;205:1681-1688.
    PubMed     Abstract available


    May 2021
  72. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
    Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
    J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
    PubMed     Abstract available


  73. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
    Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
    J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
    PubMed     Abstract available


  74. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
    Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
    J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
    PubMed     Abstract available


  75. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
    Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
    J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
    PubMed     Abstract available


  76. MACDONALD S, Matos A, Wambier C
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
    J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
    PubMed    


  77. KLEIN EA
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
    J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
    PubMed    


  78. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
    PubMed    


  79. SHAH N, Ioffe V
    Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
    J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
    PubMed    


  80. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
    J Urol. 2021;205:1528-1529.
    PubMed    


  81. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
    J Urol. 2021;205:1526-1528.
    PubMed    


  82. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
    Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
    J Urol. 2021;205:1344-1351.
    PubMed     Abstract available


  83. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed     Abstract available


    April 2021
  84. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    PubMed     Abstract available


  85. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    PubMed     Abstract available


  86. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    PubMed     Abstract available


  87. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    PubMed     Abstract available


  88. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    PubMed     Abstract available


  89. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
    Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
    J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
    PubMed     Abstract available


  90. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
    PubMed    


  91. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
    PubMed     Abstract available


  92. LIN PH, Howard L, Freedland SJ
    Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
    J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
    PubMed    


  93. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
    Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
    PubMed     Abstract available


  94. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
    Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
    J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
    PubMed     Abstract available



  95. Erratum: Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: Systematic Review and Network Meta-Analysis.
    J Urol. 2021;205:1237.
    PubMed    


  96. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 1:101097JU0000000000001746. doi: 10.1097/JU.0000000000001746.
    PubMed    


    March 2021
  97. GONG Y, Fan L, Fei X, Zhu Y, et al
    Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001731. doi: 10.1097/JU.0000000000001731.
    PubMed     Abstract available


  98. EASTHAM JA, Heller G, Hillman DW, Hahn OM, et al
    Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).
    J Urol. 2021 Mar 29:101097JU0000000000001716. doi: 10.1097/JU.0000000000001716.
    PubMed     Abstract available


  99. MCKAY RR, Xie W, Ye H, Fennessy FM, et al
    Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
    J Urol. 2021 Mar 8:101097JU0000000000001702. doi: 10.1097/JU.0000000000001702.
    PubMed     Abstract available


  100. CARROLL PR, Maggi M
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply.
    J Urol. 2021 Mar 8:101097JU0000000000001711. doi: 10.1097/JU.0000000000001711.
    PubMed    


  101. RAJWA P, Pradere B, Mori K, Ploussard G, et al
    Association of Negative Follow-Up Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and meta-Analysis.
    J Urol. 2021 Mar 8:101097JU0000000000001701. doi: 10.1097/JU.0000000000001701.
    PubMed     Abstract available


  102. MONTORSI F, Gandaglia G, Briganti A
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Letter.
    J Urol. 2021 Mar 8:101097JU0000000000001710. doi: 10.1097/JU.0000000000001710.
    PubMed    


  103. WENZEL M, Nocera L, Ruvolo CC, Wurnschimmel C, et al
    Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
    J Urol. 2021 Mar 8:101097JU0000000000001695. doi: 10.1097/JU.0000000000001695.
    PubMed     Abstract available


  104. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
    Performance of Prostate Health Index in Biopsy Naive Black Men.
    J Urol. 2021;205:718-724.
    PubMed     Abstract available


  105. UMARI P, Eden C, Cahill D, Rizzo M, et al
    Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
    J Urol. 2021;205:780-790.
    PubMed     Abstract available


  106. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
    Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    J Urol. 2021;205:732-739.
    PubMed     Abstract available


  107. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    J Urol. 2021;205:748-754.
    PubMed     Abstract available


  108. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
    Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    J Urol. 2021;205:740-747.
    PubMed     Abstract available


    February 2021
  109. PIENTA KJ, Gorin MA, Rowe SP, Carroll PR, et al
    A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY).
    J Urol. 2021 Feb 26:101097JU0000000000001698. doi: 10.1097/JU.0000000000001698.
    PubMed     Abstract available


  110. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Feb 24:101097JU0000000000001673. doi: 10.1097/JU.0000000000001673.
    PubMed    


  111. BESASIE BD, Sunnapwar AG, Gao F, Troyer D, et al
    Restriction Spectrum Imaging-MRI to Improve Prostate Cancer Imaging in Men on Active Surveillance.
    J Urol. 2021 Feb 22:101097JU0000000000001692. doi: 10.1097/JU.0000000000001692.
    PubMed     Abstract available


  112. ESKRA JN, Rabizadeh D, Zhang J, Isaacs WB, et al
    Specific Detection of Prostate Cancer Cells in Urine by RNA in Situ Hybridization.
    J Urol. 2021 Feb 22:101097JU0000000000001691. doi: 10.1097/JU.0000000000001691.
    PubMed     Abstract available


  113. BRUINSMA SM, Nieboer D, Roobol MJ, Bangma CH, et al
    Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
    J Urol. 2021 Feb 22:101097JU0000000000001700. doi: 10.1097/JU.0000000000001700.
    PubMed     Abstract available


  114. LINXWEILER J, Sprenk J, Cascetta K, Pryalukhin A, et al
    Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
    J Urol. 2021 Feb 22:101097JU0000000000001697. doi: 10.1097/JU.0000000000001697.
    PubMed     Abstract available


  115. SOUNTOULIDES P, Pyrgidis N, Polyzos SA, Mykoniatis I, et al
    Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2021 Feb 12:101097JU0000000000001639. doi: 10.1097/JU.0000000000001639.
    PubMed     Abstract available


  116. KHRIGUIAN J, Tsui JMG, Vaughan R, Kucharczyk MJ, et al
    The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    J Urol. 2021 Feb 12:101097JU0000000000001646. doi: 10.1097/JU.0000000000001646.
    PubMed     Abstract available


  117. MEIJER D, de Barros HA, van Leeuwen PJ, Bodar YJL, et al
    The Predictive Value of Preoperative Negative PSMA PET Imaging for Lymph-Node Metastatic Prostate Cancer.
    J Urol. 2021 Feb 3:101097JU0000000000001592. doi: 10.1097/JU.0000000000001592.
    PubMed     Abstract available



  118. Erratum: PI-RADS(R) Category as Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    J Urol. 2021;205:638.
    PubMed    


  119. ATALA A
    Uro-Science.
    J Urol. 2021;205:632-633.
    PubMed    


  120. KOHAAR I, Chen Y, Banerjee S, Borbiev T, et al
    A Urine Exosome Gene Expression Panel Distinguishes between Indolent and Aggressive Prostate Cancers at Biopsy.
    J Urol. 2021;205:420-425.
    PubMed     Abstract available


    January 2021
  121. CAI PY, Ma X, Christos P, Barbieri CE, et al
    Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts.
    J Urol. 2021 Jan 27:101097JU0000000000001627. doi: 10.1097/JU.0000000000001627.
    PubMed    


  122. MCKAY RR, Berchuck J, Kwak L, Xie W, et al
    Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
    J Urol. 2021 Jan 27:101097JU0000000000001632. doi: 10.1097/JU.0000000000001632.
    PubMed     Abstract available


  123. GUO B, Liu M
    Evaluation of Cancer Specific Mortality With Surgery Versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. Letter.
    J Urol. 2021 Jan 22:101097JU0000000000001636. doi: 10.1097/JU.0000000000001636.
    PubMed    


  124. WANG S, Siddiqui MM
    Evaluation of Cancer Specific Mortality With Surgery Versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. Reply.
    J Urol. 2021 Jan 22:101097JU0000000000001637. doi: 10.1097/JU.0000000000001637.
    PubMed    


  125. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jan 22:101097JU0000000000001620. doi: 10.1097/JU.0000000000001620.
    PubMed    


  126. NGUYEN DD, Haeuser L, Paciotti M, Reitblat C, et al
    Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?
    J Urol. 2021 Jan 14:101097JU0000000000001601. doi: 10.1097/JU.0000000000001601.
    PubMed     Abstract available


  127. TAN HJ
    Re:A Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
    J Urol. 2021 Jan 14:101097JU0000000000001600. doi: 10.1097/JU.0000000000001600.
    PubMed    


  128. FROEHNER M
    Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. Letter.
    J Urol. 2021 Jan 14:101097JU0000000000001599. doi: 10.1097/JU.0000000000001599.
    PubMed    



  129. Erratum: Does Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2021;205:278.
    PubMed    


  130. CHU C, Carroll P
    Editorial Comment.
    J Urol. 2021;205:121.
    PubMed    


  131. CHU CE, Cowan JE, Fasulo V, Washington SL 3rd, et al
    The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    J Urol. 2021;205:109-114.
    PubMed     Abstract available


  132. ICZKOWSKI KA, van Leenders GJLH
    Eight Endorsements of the International Society of Urological Pathology from the 2019 Consensus Conference on Grading of Prostatic Carcinoma.
    J Urol. 2021;205:8-10.
    PubMed    


    December 2020
  133. ARMSTRONG AJ, Shore ND, Szmulewitz RZ, Petrylak DP, et al
    Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    J Urol. 2020 Dec 28:101097JU0000000000001568. doi: 10.1097/JU.0000000000001568.
    PubMed     Abstract available


  134. YERRAM NK, Long L, O'Connor LP, Wang AZ, et al
    MRI-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Dec 24:101097JU0000000000001547. doi: 10.1097/JU.0000000000001547.
    PubMed     Abstract available


  135. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Dec 23:101097JU0000000000001564. doi: 10.1097/JU.0000000000001564.
    PubMed    


  136. NAHA U, Nickel JC, Andriole GL, Freedland SJ, et al
    Re: Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Dec 22:101097JU0000000000001588. doi: 10.1097/JU.0000000000001588.
    PubMed    


  137. WILT TJ, Ullman KE, Linskens EJ, MacDonald R, et al
    Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
    J Urol. 2020 Dec 22:101097JU0000000000001578. doi: 10.1097/JU.0000000000001578.
    PubMed     Abstract available


  138. STAVRINIDES V, Freeman A, Ball R, Haider A, et al
    Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Dec 22:101097JU0000000000001587. doi: 10.1097/JU.0000000000001587.
    PubMed    


  139. PIERRE-VICTOR D, Pinsky PF, Miller E, Parnes H, et al
    Other- and All-Cause Mortality Among Men Diagnosed with Prostate Cancer in the PLCO Trial.
    J Urol. 2020 Dec 22:101097JU0000000000001531. doi: 10.1097/JU.0000000000001531.
    PubMed     Abstract available


  140. SHORE N, Oliver L, Shui I, Gayle A, et al
    Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated HRR Gene Alterations.
    J Urol. 2020 Dec 17:101097JU0000000000001570. doi: 10.1097/JU.0000000000001570.
    PubMed     Abstract available


  141. ORCZYK C, Barratt D, Brew-Graves C, Peng Hu Y, et al
    Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
    J Urol. 2020 Dec 14:101097JU0000000000001567. doi: 10.1097/JU.0000000000001567.
    PubMed     Abstract available


  142. MAGGI M, Cowan JE, Fasulo V, Washington SL 3rd, et al
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020;204:1222-1228.
    PubMed     Abstract available


  143. EHDAIE B
    Editorial Comment.
    J Urol. 2020;204:1234-1235.
    PubMed    


  144. DALL'ERA MA
    Editorial Comment.
    J Urol. 2020;204:1194.
    PubMed    


  145. MORASH C
    Editorial Comment.
    J Urol. 2020;204:1221.
    PubMed    


  146. ATALA A
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-Cell Analysis.
    J Urol. 2020;204:1384.
    PubMed    


  147. JAZAYERI SB, Balaji KC
    Re: Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-AnalysisA. Pilatz, K. Dimitropoulos, R. Veeratterapillay, Y. Yuan, M. I. Omar, S. MacLennan, T. Cai, F. Bruyere, R. Barto
    J Urol. 2020;204:1349-1350.
    PubMed    


  148. GINSBURG KB, Cher ML, Montie JE
    Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2020;204:1119-1121.
    PubMed    


  149. MARRA G, Zhuang J, Marquis A, Zhao X, et al
    Pain in Men Undergoing Transperineal Free-Hand Multiparametric Magnetic Resonance Imaging Fusion Targeted Biopsies under Local Anesthesia: Outcomes and Predictors from a Multicenter Study of 1,008 Patients.
    J Urol. 2020;204:1209-1215.
    PubMed     Abstract available


  150. CONNOR MJ, Eldred-Evans D, van Son M, Hosking-Jervis F, et al
    A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
    J Urol. 2020;204:1195-1201.
    PubMed     Abstract available


  151. CULLEN J, Lynch JA, Klein EA, Van Den Eeden SK, et al
    Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in Black and White Men with Clinically Localized Prostate Cancer.
    J Urol. 2020 Dec 1:101097JU0000000000001484. doi: 10.1097/JU.0000000000001484.
    PubMed     Abstract available


  152. MEYER AR, Mamawala M, Winoker JS, Landis P, et al
    Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance.
    J Urol. 2020 Dec 1:101097JU0000000000001523. doi: 10.1097/JU.0000000000001523.
    PubMed     Abstract available


    November 2020
  153. STONE BV, Laviana AA, Luckenbaugh AN, Huang LC, et al
    Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
    J Urol. 2020 Nov 30:101097JU0000000000001423. doi: 10.1097/JU.0000000000001423.
    PubMed     Abstract available


  154. DEWITT-FOY ME, Gam K, Modlin C, Kim SP, et al
    Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.
    J Urol. 2020 Nov 23:101097JU0000000000001385. doi: 10.1097/JU.0000000000001385.
    PubMed     Abstract available


  155. STONIER T, Tin AL, Sjoberg DD, Jibara G, et al
    Selecting Patients with Favourable-Risk, GG2 Prostate Cancer for Active Surveillance: Does MRI Have a Role?
    J Urol. 2020 Nov 20:101097JU0000000000001519. doi: 10.1097/JU.0000000000001519.
    PubMed     Abstract available


  156. CHEN M, Zhuang J, Fu Y, Guo S, et al
    Can (68)Ga-PSMA-11 PET/CT Predict Pathologic Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy: A Pilot Study.
    J Urol. 2020 Nov 18:101097JU0000000000001481. doi: 10.1097/JU.0000000000001481.
    PubMed     Abstract available


  157. MEIJER D, Luiting HB, van Leeuwen PJ, Remmers S, et al
    PSMA PET/CT in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
    J Urol. 2020 Nov 18:101097JU0000000000001437. doi: 10.1097/JU.0000000000001437.
    PubMed     Abstract available


  158. KHOO CC, Eldred-Evans D, Peters M, van Son M, et al
    A Comparison of Prostate Cancer Detection Between Visual-Estimation (Cognitive Registration) and Image-Fusion (Software Registration) Targeted Transperineal Prostate Biopsy.
    J Urol. 2020 Nov 18:101097JU0000000000001476. doi: 10.1097/JU.0000000000001476.
    PubMed     Abstract available


  159. WIBMER AG, Chaim J, Lakhman Y, Lefkowitz R, et al
    Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pre-treatment Prostate MRI Findings.
    J Urol. 2020 Nov 18:101097JU0000000000001474. doi: 10.1097/JU.0000000000001474.
    PubMed     Abstract available


  160. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Nov 17:101097JU0000000000001501. doi: 10.1097/JU.0000000000001501.
    PubMed    


  161. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Nov 12:101097JU0000000000001472. doi: 10.1097/JU.0000000000001472.
    PubMed    


  162. POWELL IJ, Heilbrun LK, Kittles RA
    RE: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from Canary Prostate Cancer Active Surveillance Study.
    J Urol. 2020 Nov 6:101097JU0000000000001443. doi: 10.1097/JU.0000000000001443.
    PubMed    


  163. SCHENK JM, Newcomb LF, Zhu K, Zheng Y, et al
    Re: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    J Urol. 2020 Nov 6:101097JU0000000000001444. doi: 10.1097/JU.0000000000001444.
    PubMed    



  164. Erratum: Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
    J Urol. 2020;204:1069.
    PubMed    


  165. BIANCO FJ JR
    Editorial Comment.
    J Urol. 2020;204:948-949.
    PubMed    


  166. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2020;204:949.
    PubMed    


  167. BASILE G, Bandini M
    Editorial Comment.
    J Urol. 2020;204:967-968.
    PubMed    


  168. PREISSER F
    Editorial Comment.
    J Urol. 2020;204:967.
    PubMed    


  169. MIURA N, Mori K, Mostafaei H, Quhal F, et al
    The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:909-917.
    PubMed     Abstract available


  170. KANTHABALAN A, Arya M, Freeman A, Mitra AV, et al
    Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.
    J Urol. 2020;204:950-955.
    PubMed     Abstract available


  171. PLOUSSARD G, Dumonceau O, Thomas L, Benamran D, et al
    Multi-Institutional Assessment of Routine Same Day Discharge Surgery for Robot-Assisted Radical Prostatectomy.
    J Urol. 2020;204:956-961.
    PubMed     Abstract available


  172. MONAGHAN TF, Weiss JP, Wein AJ
    Re: Impact of Nocturia on Mortality: The Nagahama StudyS. Funada, Y. Tabara, K. Setoh, H. Negoro, S. Akamatsu, T. Yoshino, K. Yoshimura, N. Watanabe, T. A. Furukawa, F. Matsuda and O. Ogawa J Urol 2020; doi: 10.1097/JU.0000000000001138.
    J Urol. 2020;204:1067-1068.
    PubMed    


    October 2020
  173. CRAWFORD ED, Hafron JM, Tagawa ST, Twardowski PW, et al
    Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data.
    J Urol. 2020 Oct 22:101097JU0000000000001392. doi: 10.1097/JU.0000000000001392.
    PubMed     Abstract available


  174. BUISSET J, Norris JM, Puech P, Leroy X, et al
    Negative Pre-biopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Follow-up Results.
    J Urol. 2020 Oct 20:101097JU0000000000001414. doi: 10.1097/JU.0000000000001414.
    PubMed     Abstract available


  175. NAHA U, Nickel JC, Andriole GL, Freedland SJ, et al
    Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Oct 20:101097JU0000000000001407. doi: 10.1097/JU.0000000000001407.
    PubMed     Abstract available


  176. XU MC, Huelster HL, Hatcher JB, Avulova S, et al
    Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
    J Urol. 2020 Oct 20:101097JU0000000000001428. doi: 10.1097/JU.0000000000001428.
    PubMed     Abstract available


  177. PATEL A
    Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naive Advanced Prostate Cancer Patients?
    J Urol. 2020 Oct 9:101097JU0000000000001413. doi: 10.1097/JU.0000000000001413.
    PubMed     Abstract available


  178. CARLSSON SV, Touijer K
    Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    J Urol. 2020 Oct 9:101097JU0000000000001421. doi: 10.1097/JU.0000000000001421.
    PubMed    


  179. MONTORSI F, Gandaglia G, Fossati N, Briganti A, et al
    Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol. 2020;203(6):1122-7.
    J Urol. 2020 Oct 9:101097JU0000000000001420. doi: 10.1097/JU.0000000000001420.
    PubMed    


  180. POOLI A, Johnson DC, Shirk J, Markovic D, et al
    Predicting Pathologic Tumor Size in Prostate Cancer Based on Multiparametric Prostate MRI and Preoperative Findings.
    J Urol. 2020 Oct 7:101097JU0000000000001389. doi: 10.1097/JU.0000000000001389.
    PubMed     Abstract available



  181. Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Oct 7:101097JU0000000000001403. doi: 10.1097/JU.0000000000001403.
    PubMed    


  182. MOROTE J, Comas I
    Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Oct 7:101097JU0000000000001402. doi: 10.1097/JU.0000000000001402.
    PubMed    


  183. RIBEIRO L, Stonier T, Stroman L, Tourinho-Barbosa R, et al
    Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?
    J Urol. 2020 Oct 6:101097JU0000000000001382. doi: 10.1097/JU.0000000000001382.
    PubMed     Abstract available


  184. KLOTZ L, Pavlovich CP, Chin J, Hatiboglu G, et al
    MRI-guided transurethral ultrasound ablation of prostate cancer.
    J Urol. 2020 Oct 6:101097JU0000000000001362. doi: 10.1097/JU.0000000000001362.
    PubMed     Abstract available


  185. ABREU AL, Peretsman S, Iwata A, Shakir A, et al
    High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
    J Urol. 2020;204:741-747.
    PubMed     Abstract available


  186. GINSBURG KB, Curtis GL, Timar RE, George AK, et al
    Delayed Radical Prostatectomy is Not Associated with Adverse Oncologic Outcomes: Implications for Men Experiencing Surgical Delay Due to the COVID-19 Pandemic.
    J Urol. 2020;204:720-725.
    PubMed     Abstract available


  187. HELFAND BT, Glaser AP
    Editorial Comment.
    J Urol. 2020;204:700.
    PubMed    


  188. LOPEZ F, Macpherson R, Lamb A
    Editorial Comment.
    J Urol. 2020;204:670.
    PubMed    


  189. VALERIO M
    Editorial Comment.
    J Urol. 2020;204:747.
    PubMed    


  190. BARBIERI CE
    Editorial Comment.
    J Urol. 2020;204:712-713.
    PubMed    


  191. MANO R
    Editorial Comment.
    J Urol. 2020;204:713.
    PubMed    


  192. GINSBURG KB, Curtis GL, Timar RE, George AK, et al
    Reply by Authors.
    J Urol. 2020;204:845.
    PubMed    


  193. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed     Abstract available


  194. LISS MA, Newcomb LF, Zheng Y, Garcia MP, et al
    Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2020;204:701-706.
    PubMed     Abstract available


  195. RODRIGUEZ SOCARRAS ME, Gomez Rivas J, Cuadros Rivera V, Reinoso Elbers J, et al
    Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using Multiparametric Magnetic Resonance Imaging Fusion and Micro-Ultrasound Guided Biopsies.
    J Urol. 2020;204:726-733.
    PubMed     Abstract available


    September 2020
  196. CHUANG R, Kinnaird A, Kwan L, Sisk A, et al
    Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
    J Urol. 2020 Sep 28:101097JU0000000000001133. doi: 10.1097/JU.0000000000001133.
    PubMed     Abstract available


  197. TANEJA SS
    Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel.
    J Urol. 2020 Sep 22:101097JU0000000000001283. doi: 10.1097/JU.0000000000001283.
    PubMed    


  198. TANEJA SS
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    J Urol. 2020 Sep 22:101097JU000000000000128302.
    PubMed    


  199. TANEJA SS
    Re: Facility-Level Variation in Pelvic Lymphadenectomy during Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer.
    J Urol. 2020 Sep 22:101097JU000000000000128301.
    PubMed    


  200. LOWRANCE WT, Breau RH, Chou R, Chapin BF, et al
    Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
    J Urol. 2020 Sep 22:101097JU0000000000001375. doi: 10.1097/JU.0000000000001375.
    PubMed     Abstract available


  201. LOWRANCE WT, Breau RH, Chou R, Chapin BF, et al
    Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
    J Urol. 2020 Sep 22:101097JU0000000000001376. doi: 10.1097/JU.0000000000001376.
    PubMed     Abstract available


  202. ELLIOTT SP
    Re: Magnetic Resonance Imaging Features of Pubic Symphysis Urinary Fistula with Pubic Bone Osteomyelitis in the Treated Prostate Cancer Patient.
    J Urol. 2020 Sep 21:101097JU000000000000127901.
    PubMed    


  203. SIEGEL C
    Re: Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Sep 21:101097JU0000000000001271. doi: 10.1097/JU.0000000000001271.
    PubMed    


  204. CROCEROSSA F, Marchioni M, Novara G, Carbonara U, et al
    Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    J Urol. 2020 Sep 16:101097JU0000000000001369. doi: 10.1097/JU.0000000000001369.
    PubMed     Abstract available


  205. TAN HJ, Zhou X, Spratte BN, McMahon S, et al
    Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
    J Urol. 2020 Sep 10:101097JU0000000000001355. doi: 10.1097/JU.0000000000001355.
    PubMed     Abstract available


  206. FAN L, Fei X, Zhu Y, Pan J, et al
    Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing.
    J Urol. 2020 Sep 8:101097JU0000000000001363. doi: 10.1097/JU.0000000000001363.
    PubMed     Abstract available


  207. DE LA CALLE CM, Fasulo V, Cowan JE, Lonergan PE, et al
    Clinical Utility of 4Kscore, ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High-Grade Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001361. doi: 10.1097/JU.0000000000001361.
    PubMed     Abstract available


  208. CHEN Y, Wu X, Yan W
    RE: Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Sep 8:101097JU0000000000001348. doi: 10.1097/JU.0000000000001348.
    PubMed    


  209. KLEIN EA, Li J, Milinovich A, Schold JD, et al
    Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2.
    J Urol. 2020 Sep 8:101097JU0000000000001338. doi: 10.1097/JU.0000000000001338.
    PubMed     Abstract available


  210. TANEJA SS
    Re: Association of Presalvage Radiotherapy PSA Levels after Prostatectomy with Outcomes of Long-Term Antiandrogen Therapy in Men with Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001261. doi: 10.1097/JU.0000000000001261.
    PubMed    


  211. TANEJA SS
    Re: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU000000000000126101.
    PubMed    


  212. ALGHAZO O, Cumberbatch M, Murphy DG
    Editorial Comment.
    J Urol. 2020;204:502.
    PubMed    


  213. VILLERS A, Olivier J
    Editorial Comment.
    J Urol. 2020;204:489.
    PubMed    


  214. SIEGEL C
    Re: Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
    J Urol. 2020;204:597.
    PubMed    


  215. HELFAND B
    Editorial Comment.
    J Urol. 2020;204:474-475.
    PubMed    


  216. MONTORSI F, Capogrosso P
    Re: The Impact of Nocturia on Mortality: A Systematic Review and Meta-AnalysisJ. S. Pesonen, R. Cartwright, R. W. M. Vernooij, Y. Aoki, A. Agarwal, A. Mangera, A. D. Markland, J. F. Tsui, H. Santti, T. L. Griebling, A. E. Pryalukhin, J. Riikonen, R. M
    J Urol. 2020;204:589-590.
    PubMed    


  217. AHMAD AE, Richard PO, Leao R, Hajiha M, et al
    Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
    J Urol. 2020;204:476-482.
    PubMed     Abstract available


  218. DASKIVICH TJ, Howard LE, Amling CL, Aronson WJ, et al
    Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2020;204:511-517.
    PubMed     Abstract available


  219. LUITING HB, van Leeuwen PJ, Remmers S, Donswijk M, et al
    Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2020;204:503-510.
    PubMed     Abstract available


  220. SAIDIAN A, Fang AM, Hakim O, Magi-Galluzzi C, et al
    Perioperative Outcomes of Single vs Multi-Port Robotic Assisted Radical Prostatectomy: A Single Institutional Experience.
    J Urol. 2020;204:490-495.
    PubMed     Abstract available


    August 2020
  221. SARI MOTLAGH R, Quhal F, Mori K, Miura N, et al
    The Risk of New Onset Dementia And/Or Alzheimer's Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2020 Aug 28:101097JU0000000000001341. doi: 10.1097/JU.0000000000001341.
    PubMed     Abstract available


  222. GRIEBLING TL
    Re: Frailty Syndrome is Associated with Changes in Peripheral Inflammatory Markers in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.
    J Urol. 2020 Aug 26:101097JU000000000000124803.
    PubMed    


  223. GRIEBLING TL
    Re: Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia.
    J Urol. 2020 Aug 26:101097JU000000000000124804.
    PubMed    


  224. GRIEBLING TL
    Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
    J Urol. 2020 Aug 26:101097JU0000000000001248. doi: 10.1097/JU.0000000000001248.
    PubMed    


  225. GRIEBLING TL
    Re: Pre-Diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.
    J Urol. 2020 Aug 26:101097JU000000000000124801.
    PubMed    


  226. GRIEBLING TL
    Re: Clinical-Genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-Grade Disease.
    J Urol. 2020 Aug 26:101097JU000000000000124802.
    PubMed    


  227. ATALA A
    Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU0000000000001263. doi: 10.1097/JU.0000000000001263.
    PubMed    


  228. ATALA A
    Re: Genome-Wide Plasma DNA Methylation Features of Metastatic Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126301.
    PubMed    


  229. BORGES RC, Tourinho-Barbosa RR, Glina S, Macek P, et al
    Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.
    J Urol. 2020 Aug 17:101097JU0000000000001327. doi: 10.1097/JU.0000000000001327.
    PubMed     Abstract available


  230. PANER GP
    Editorial Comment.
    J Urol. 2020;204:265-266.
    PubMed    


  231. EGGENER S
    Editorial Comment.
    J Urol. 2020;204:287.
    PubMed    


  232. REESE AC
    Editorial Comment.
    J Urol. 2020;204:302.
    PubMed    


  233. CHANDRASEKAR T
    Editorial Comment.
    J Urol. 2020;204:301-302.
    PubMed    


  234. NYAME YA
    Editorial Comment.
    J Urol. 2020;204:280.
    PubMed    


  235. MORASH C
    Editorial Comment.
    J Urol. 2020;204:279-280.
    PubMed    


  236. BRONKEMA C, Arora S, Sood A, Dalela D, et al
    Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis.
    J Urol. 2020;204:260-266.
    PubMed     Abstract available


  237. WOON DTS, Herrera-Caceres JO, Goldberg H, Shiakh H, et al
    A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
    J Urol. 2020;204:289-295.
    PubMed     Abstract available


    July 2020
  238. GREGG JR, Surasi DS, Childs A, Moll N, et al
    The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001321. doi: 10.1097/JU.0000000000001321.
    PubMed     Abstract available


  239. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Risk Stratification of Prostate Cancer According to PI-RADS Version 2 Categories: Meta-Analysis for Prospective Studies.
    J Urol. 2020 Jul 27:101097JU0000000000001306. doi: 10.1097/JU.0000000000001306.
    PubMed     Abstract available


  240. SONG G, Ruan M, Wang H, Fan Y, et al
    How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    J Urol. 2020 Jul 27:101097JU0000000000001302. doi: 10.1097/JU.0000000000001302.
    PubMed     Abstract available


  241. WANG AZ, O'Connor LP, Yerram NK, Long L, et al
    PIRADS Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001307. doi: 10.1097/JU.0000000000001307.
    PubMed     Abstract available


  242. TANEJA SS
    Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    J Urol. 2020 Jul 27:101097JU000000000000122001.
    PubMed    


  243. TANEJA SS
    Re: Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001220. doi: 10.1097/JU.0000000000001220.
    PubMed    


  244. TANEJA SS
    Re: Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men with Locally Advanced Prostate Cancer: 10-Year Data from the TROG 03.04 RADAR Trial.
    J Urol. 2020 Jul 27:101097JU000000000000122002.
    PubMed    


  245. ATALA A
    Re: OXPHOS Remodeling in High-Grade Prostate Cancer Involves mtDNA Mutations and Increased Succinate Oxidation.
    J Urol. 2020 Jul 24:101097JU0000000000001222. doi: 10.1097/JU.0000000000001222.
    PubMed    


  246. GRIEBLING TL
    Re: Home-Based 'Exergaming' Was Safe and Significantly Improved 6-Min Walking Distance in Patients with Prostate Cancer: A Single-Blinded Randomised Controlled Trial.
    J Urol. 2020 Jul 23:101097JU000000000000120703.
    PubMed    


  247. DENIFFEL D, Haider M, Perlis N
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001296. doi: 10.1097/JU.0000000000001296.
    PubMed    


  248. STAVRINIDES V, Giganti F, Punwani S, Allen C, et al
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001295. doi: 10.1097/JU.0000000000001295.
    PubMed    


  249. CARLSSON SV, Touijer K
    Re: Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with AS at a Tertiary Cancer Center.
    J Urol. 2020 Jul 23:101097JU0000000000001292. doi: 10.1097/JU.0000000000001292.
    PubMed    


  250. SHAH N, Ioffe V
    Re: Risk of metastasis in men with Grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center.
    J Urol. 2020 Jul 23:101097JU0000000000001291. doi: 10.1097/JU.0000000000001291.
    PubMed    


  251. AGRAWAL V, Ma X, Hu JC, Barbieri CE, et al
    Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    J Urol. 2020 Jul 13:101097JU0000000000001241. doi: 10.1097/JU.0000000000001241.
    PubMed     Abstract available


  252. KINNAIRD A, Sharma V, Chuang R, Priester A, et al
    Risk of Prostate Cancer after a Negative MRI-Guided Biopsy.
    J Urol. 2020 Jul 2:101097JU0000000000001232. doi: 10.1097/JU.0000000000001232.
    PubMed     Abstract available


  253. MOSCHINI M, Rozet F
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


  254. KILPELAINEN T, Lahdensuo K, Rannikko A
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


  255. PAGNIEZ MA, Kasivisvanathan V, Puech P, Drumez E, et al
    Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:24-32.
    PubMed     Abstract available


  256. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;204:77.
    PubMed    


  257. SPRATT DE
    Editorial Comment.
    J Urol. 2020;204:89-90.
    PubMed    


  258. FALAGARIO UG, Ratnani P, Lantz A, Jambor I, et al
    Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
    J Urol. 2020;204:82-90.
    PubMed     Abstract available


  259. SOETERIK TFW, van Melick HHE, Dijksman LM, Stomps S, et al
    Nerve Sparing during Robot-Assisted Radical Prostatectomy Increases the Risk of Ipsilateral Positive Surgical Margins.
    J Urol. 2020;204:91-95.
    PubMed     Abstract available


  260. CADEDDU JA
    Re: Comparison of Outcomes of Salvage Robot-Assisted Laparoscopic Prostatectomy for Post-Primary Radiation vs Focal Therapy.
    J Urol. 2020;204:168.
    PubMed    


  261. HAJIRAN A, Pow-Sang J
    Re: Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;204:159.
    PubMed    


  262. FULLER TW, Ballon-Landa E, Gallo K, Smith TG 3rd, et al
    Outcomes and Risk Factors of Revision and Replacement Artificial Urinary Sphincter Implantation in Radiated and Nonradiated Cases.
    J Urol. 2020;204:110-114.
    PubMed     Abstract available


    June 2020
  263. RESNICK MJ
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Jun 26:101097JU0000000000001171. doi: 10.1097/JU.0000000000001171.
    PubMed    


  264. TANEJA SS
    Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    J Urol. 2020 Jun 26:101097JU000000000000117601.
    PubMed    


  265. TANEJA SS
    Re: Validation of a Subclassification for High-Risk Prostate Cancer in a Prospective Cohort.
    J Urol. 2020 Jun 26:101097JU0000000000001176. doi: 10.1097/JU.0000000000001176.
    PubMed    


  266. TANEJA SS
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-Based, Diagnostic Study.
    J Urol. 2020 Jun 26:101097JU000000000000117602.
    PubMed    


  267. REISZ PA, Laviana AA, Zhao Z, Huang LC, et al
    Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study.
    J Urol. 2020 Jun 22:101097JU0000000000001198. doi: 10.1097/JU.0000000000001198.
    PubMed     Abstract available


  268. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Inter-reader Agreement in Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2020 Jun 18:101097JU0000000000001200. doi: 10.1097/JU.0000000000001200.
    PubMed     Abstract available


  269. ATALA A
    Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-kappaB Activation.
    J Urol. 2020 Jun 18:101097JU0000000000001179. doi: 10.1097/JU.0000000000001179.
    PubMed    


  270. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020 Jun 10:101097JU0000000000001186. doi: 10.1097/JU.0000000000001186.
    PubMed     Abstract available


  271. DENIFFEL D, Salinas E, Ientilucci M, Evans AJ, et al
    Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jun 4:101097JU0000000000001157. doi: 10.1097/JU.0000000000001157.
    PubMed     Abstract available


  272. O'NEIL B
    Editorial Comment.
    J Urol. 2020;203:1116.
    PubMed    


  273. CARROLL PR, Chu C
    Editorial Comment.
    J Urol. 2020;203:1121.
    PubMed    


  274. SAIDIAN A, Vishwanath V, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2020;203:1092-1093.
    PubMed    


  275. KAOUK J, Aminsharifi A, Wilson CA, Sawczyn G, et al
    Extraperitoneal versus Transperitoneal Single Port Robotic Radical Prostatectomy: A Comparative Analysis of Perioperative Outcomes.
    J Urol. 2020;203:1135-1140.
    PubMed     Abstract available


  276. MOTTERLE G, Ahmed ME, Andrews JR, Moschini M, et al
    Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution.
    J Urol. 2020;203:1141-1146.
    PubMed     Abstract available


    May 2020
  277. GIRI VN, Hyatt C, Leader A
    Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
    J Urol. 2020 May 27:101097JU0000000000001150. doi: 10.1097/JU.0000000000001150.
    PubMed    


  278. TANEJA SS
    Re: Influence of the Facility Caseload on the Subsequent Survival of Men with Localized Prostate Cancer Undergoing Radical Prostatectomy.
    J Urol. 2020 May 13:101097JU000000000000111502.
    PubMed    


  279. TANEJA SS
    Re: Utility of Multiparametric Magnetic Resonance Imaging in the Risk Stratification of Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2020 May 13:101097JU0000000000001115. doi: 10.1097/JU.0000000000001115.
    PubMed    


  280. TANEJA SS
    Re: Prostate Cancer Mortality and Metastasis under Different Biopsy Frequencies in North American Active Surveillance Cohorts.
    J Urol. 2020 May 13:101097JU000000000000111501.
    PubMed    


  281. GRIEBLING TL
    Re: Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 Years and Older with Non-Metastatic Prostate Cancer? National Survey.
    J Urol. 2020 May 13:101097JU000000000000110201.
    PubMed    


  282. GRIEBLING TL
    Re: Patients with Prostate Cancer and Androgen Deprivation Therapy Have Increased Risk of Fractures-A Study from the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO).
    J Urol. 2020 May 13:101097JU000000000000110202.
    PubMed    


  283. GRIEBLING TL
    Re: Osteoporosis and Prostate Cancer; A 24-Month Prospective Observational Study during Androgen Deprivation Therapy.
    J Urol. 2020 May 13:101097JU000000000000110203.
    PubMed    


  284. GRIEBLING TL
    Re: Low-Value Prostate Cancer Screening among Older Men within the Veterans Health Administration.
    J Urol. 2020 May 13:101097JU0000000000001102. doi: 10.1097/JU.0000000000001102.
    PubMed    


  285. ATALA A
    Re: Galpha-13 Induces C X C Motif Chemokine Ligand 5 Expression in Prostate Cancer Cells by Transactivating NF-kappaB.
    J Urol. 2020 May 12:101097JU000000000000111702.
    PubMed    


  286. STOLZENBACH LF, Rosiello G, Deuker M, Colla-Ruvolo C, et al
    The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer.
    J Urol. 2020 May 12:101097JU0000000000001131. doi: 10.1097/JU.0000000000001131.
    PubMed     Abstract available


  287. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 5:101097JU0000000000001123. doi: 10.1097/JU.0000000000001123.
    PubMed    


  288. MARKS LS, Natarajan S
    RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2020 May 4:101097JU0000000000001124. doi: 10.1097/JU.0000000000001124.
    PubMed    


  289. GANDAGLIA G, Briganti A, Fossati N, Montorsi F, et al
    Re: Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 4:101097JU0000000000001122. doi: 10.1097/JU.0000000000001122.
    PubMed    


  290. SCHAEFFER EM
    Re: Multiparametric MRI Appearances of Primary Granulomatous Prostatitis.
    J Urol. 2020;203:862.
    PubMed    


  291. MARKS LS, Kinnaird A
    Editorial Comment.
    J Urol. 2020;203:924.
    PubMed    


  292. GHAI S
    Editorial Comment.
    J Urol. 2020;203:923-924.
    PubMed    


  293. SCHAEFFER EM
    Re: Sustained Influence of Infections on Prostate-Specific Antigen Concentration: An Analysis of Changes over 10 Years of Follow-up.
    J Urol. 2020;203:861-862.
    PubMed    


  294. JONES JS
    Editorial Comment.
    J Urol. 2020;203:938-939.
    PubMed    


  295. XIA L, Sperling CD, Taylor BL, Talwar R, et al
    Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy.
    J Urol. 2020;203:926-932.
    PubMed     Abstract available


  296. POULIOT F, Rouleau M, Neveu B, Toren P, et al
    Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
    J Urol. 2020;203:940-948.
    PubMed     Abstract available


  297. AMIN A, Scheltema MJ, Shnier R, Blazevski A, et al
    The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    J Urol. 2020;203:910-917.
    PubMed     Abstract available


    April 2020
  298. ALEMOZAFFAR M, Akintayo AA, Abiodun-Ojo OA, Patil D, et al
    [(18)F]fluciclovine PET/CT for Preoperative Staging in Patients with Intermediate to High-Risk Primary Prostate Cancer.
    J Urol. 2020 Apr 29:101097JU0000000000001095. doi: 10.1097/JU.0000000000001095.
    PubMed     Abstract available


  299. DETSKY JS, Ghiam AF, Mamedov A, Commisso K, et al
    Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Apr 24:101097JU0000000000001091. doi: 10.1097/JU.0000000000001091.
    PubMed     Abstract available


  300. TANEJA SS
    Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate Cancer.
    J Urol. 2020 Apr 15:101097JU000000000000105602.
    PubMed    


  301. TANEJA SS
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Apr 15:101097JU0000000000001056. doi: 10.1097/JU.0000000000001056.
    PubMed    


  302. TANEJA SS
    Re: Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    J Urol. 2020 Apr 15:101097JU000000000000105601.
    PubMed    


  303. MONTORSI F, Fossati N, Gandaglia G, Briganti A, et al
    (68)Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications.
    J Urol. 2020 Apr 13:101097JU0000000000001081. doi: 10.1097/JU.0000000000001081.
    PubMed    


  304. ATALA A
    Re: miR-191 Promotes Radiation Resistance of Prostate Cancer through Interaction with RXRA.
    J Urol. 2020 Apr 9:101097JU000000000000105801.
    PubMed    


  305. RANASINGHE W, Reichard CA, Nyame YA, Sundi D, et al
    Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
    J Urol. 2020 Apr 7:101097JU0000000000001074. doi: 10.1097/JU.0000000000001074.
    PubMed     Abstract available


  306. WOO J, Santasusagna S, Banks J, Pastor-Lopez S, et al
    Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001066. doi: 10.1097/JU.0000000000001066.
    PubMed     Abstract available


  307. MARKOWSKI MC, Sedhom R, Fu W, Gray JCR, et al
    PSA and PSA Doubling Time Predict Findings on (18)F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001064. doi: 10.1097/JU.0000000000001064.
    PubMed     Abstract available


  308. BONDE MIRANDA T, Garmo H, Stattin P, Robinson D, et al
    5alpha-Reductase Inhibitors and Risk of Prostate Cancer Death.
    J Urol. 2020 Apr 3:101097JU0000000000001038. doi: 10.1097/JU.0000000000001038.
    PubMed     Abstract available


  309. TOSOIAN JJ
    Editorial Comment.
    J Urol. 2020;203:732.
    PubMed    


  310. KLAASSEN Z, Wallis CJD
    Editorial Comment.
    J Urol. 2020;203:758-759.
    PubMed    


  311. STEYERBERG EW
    Editorial Comment.
    J Urol. 2020;203:726.
    PubMed    


  312. MEHRALIVAND S
    Editorial Comment.
    J Urol. 2020;203:725-726.
    PubMed    


  313. LEAPMAN M
    Editorial Comment.
    J Urol. 2020;203:705.
    PubMed    


  314. NELSON M, Dornbier R, Kirshenbaum E, Eguia E, et al
    Use of Surgery for Post-Prostatectomy Incontinence.
    J Urol. 2020;203:786-791.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: